



Preliminary assessment of the therapeutic potential of staphylococcal enterotoxin-like W via biological activity and TCR binding sites analysis

Yuhua Yang , Xiaoyue Wei , Fanliang Meng , Yanan Gong , Yahui Guo , Lijin Long , Jiaming Fan , Yakun Zhao , Wanting Wang , Di Xiao, Lei Wang , Maojun Zhang , Dongliang Hu , Jianzhong Zhang & Xiaomei Yan

To cite this article: Yuhua Yang , Xiaoyue Wei , Fanliang Meng , Yanan Gong , Yahui Guo , Lijin Long , Jiaming Fan , Yakun Zhao , Wanting Wang , Di Xiao, Lei Wang , Maojun Zhang , Dongliang Hu , Jianzhong Zhang & Xiaomei Yan (2025) Preliminary assessment of the therapeutic potential of staphylococcal enterotoxin-like W via biological activity and TCR binding sites analysis, *Virulence*, 16:1, 2550622, DOI: [10.1080/21505594.2025.2550622](https://doi.org/10.1080/21505594.2025.2550622)

To link to this article: <https://doi.org/10.1080/21505594.2025.2550622>



© 2025 National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention. Published by Informa UK Limited, trading as Taylor & Francis Group.



[View supplementary material](#)



Published online: 31 Aug 2025.



[Submit your article to this journal](#)



Article views: 400



[View related articles](#)



[View Crossmark data](#)

Preliminary assessment of the therapeutic potential of staphylococcal enterotoxin-like W via biological activity and TCR binding sites analysis

Yuhua Yang^a, Xiaoyue Wei^a, Fanliang Meng^a, Yanan Gong^a, Yahui Guo^{a,b}, Lijin Long^{a,c}, Jiaming Fan^a, Yakun Zhao^{a,c}, Wanting Wang^a, Di Xiao , Lei Wang^a, Maojun Zhang^a, Dongliang Hu^d, Jianzhong Zhang , and Xiaomei Yan 

^aNational Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China; ^bInfectious Disease Prevention and Control Department, Bayannur Center for Disease Control and Prevention, Inner Mongolia Autonomous Region, China; ^cSchool of Public Health, China Medical University, Shenyang, China; ^dDepartment of Zoonoses, Kitasato University School of Veterinary Medicine, Towada, Japan

ABSTRACT

Staphylococcal enterotoxin-like W (SEIW) is a novel, widely prevalent enterotoxin-like protein that functions as a classical staphylococcal superantigen (SAg) and has been shown to exacerbate infections caused by the *S. aureus* epidemic clone CC398. However, the genetic distribution and amino acid polymorphisms, biological and antitumor activity, and T cell receptor (TCR) binding sites of SEIW in *S. aureus* strains prevalent in China have not been investigated. The carrier rate and distribution of *selw* were determined by PCR, the stability and antitumor activity of recombinant SEIW (rSEIW) protein were evaluated. The superantigen activity of the five mutants (Y18A, N19A, W55A, C88A, and C98A) was compared to that of wild-type SEIW (WT-rSEIW) to assess the role of these sites in mediating TCR binding. The *selw* gene was detected in all (986/986, 100%) dominant clonal lineages of *S. aureus* and most strains (69.1%, 56/81) had a full-length *selw* open reading frame with a sequence identity of 90.5%. rSEIW was heat-stable but not resistant to pepsin and trypsin digestion. Additionally, rSEIW significantly inhibited the proliferation of MCF-7 and AGS, but not A549 *in vitro*. The rSEIW mutants C88A and C98A markedly reduced T cell proliferation and IL-2, IFN- γ and TNF- α secretion compared to WT-rSEIW. rSEIW is a highly prevalent SAg that binds to the TCR via C98 and C88, which may serve as novel therapeutic targets for *S. aureus* infections and its application in anti-tumor activity needs to be further evaluated *in vivo*.

ARTICLE HISTORY

Received 18 February 2025
Revised 27 June 2025
Accepted 14 August 2025

KEYWORDS

Superantigen;
staphylococcal enterotoxin-like W; sequence polymorphism; stability; site-directed mutagenesis; antitumor

Introduction

Staphylococcus aureus is an opportunistic pathogenic bacterium that colonizes the nasal vestibular mucosa and various skin surfaces in humans [1–3] and can cause skin and soft tissue infections, endocarditis, and bacteremia [4–6]. *S. aureus* infects the host and secretes a wide range of virulence factors, including hemolysins, exfoliative toxins, and staphylococcal superantigens (SAGs) [7,8]. SAGs, including staphylococcal enterotoxins (SEs), staphylococcal enterotoxin-like toxins (SEIs), and toxic shock syndrome toxin-1 [9,10], are potent T cell mitogens that bind directly to major histocompatibility complex class II (MHC-II) molecules on antigen-presenting cells and form bridges with the variable regions of the T cell receptor (TCR) α - or β -chain without undergoing antigen processing and presentation [11,12]. This interaction induces abnormally rapid proliferation of T cells and massive release of pro-inflammatory cytokines such as interleukin-2 (IL-2), IL-4, tumor necrosis factor (TNF), and interferon- γ (IFN- γ) [13–15].

At least 29 enterotoxins with superantigenic and emetic properties have been reported. Enterotoxins demonstrated to induce emesis in mammals are designated as “SEs,” which include SEA-SEE [16], SEG-SEI [17,18], SEK-SEQ [19,20], SER-SET [21,22], SEY [23], SE01, and SE02 [24]. In contrast, those without emetic properties or not evaluated in non-human primate models of emesis are designated as SEIs, such as SEI, SEIU-SEIX, SEIZ, SEI26, and SEI27 [25–27]. SEs and SEIs are structurally similar in that they are non-glycosylated single-chain homologous globular proteins with distinct antigenicity and low molecular weight (19–29 kDa) [28].

SEs not only activate T cells to secrete cytokines that inhibit tumor growth but also stimulate cytotoxic T cells to kill MHC II-positive tumors under low-dose conditions, making them effective antitumor agents [29]. In China, staphylococcal enterotoxin C2 (SEC2) injection has been used in cancer treatment since 1999 [30,31]. Additionally, SEs have been shown to act synergistically with antibodies to recruit T cells [32]. However, the toxic side effects such

CONTACT Xiaomei Yan  yanxiaomei@icdc.cn

 Supplemental data for this article can be accessed online at <https://doi.org/10.1080/21505594.2025.2550622>

© 2025 National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention. Published by Informa UK Limited, trading as Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.

as the emetic activity and strong superantigenic reaction of enterotoxin itself have limited its clinical application. The identification of enterotoxins exhibiting low cytotoxic potential while maintaining potent antitumor efficacy represents a scientifically valuable research direction in oncotherapeutic discovery.

Identifying the TCR binding sites for SEs is crucial for gaining insights into their structural and functional activities, as well as their mechanisms of immune recognition, which will aid in developing SAGs antagonists and enhancing their anticancer potency. Protein structure prediction and site-directed mutagenesis are two common techniques for studying TCR binding sites. Xu et al. revealed that the TCR binding sites on SAGs are located within a shallow groove between two domains of the staphylococcal SAGs [10]. These binding sites are characterized by several cross-interface bonds, with N23 of SEB and SEC2, or N16 of SEH, identified as the key residue mediating TCR binding. SEIW is a newly identified enterotoxin-like toxin that shares 36% homology with SEA [33]. Extensive genomic data analysis showed that the *selw* is present in over 90% of *S. aureus* isolates and in almost all dominant clonal lineages of *S. aureus* [13,34–36]. Research has shown that SEIW exhibits superantigenicity and induces massive T cell proliferation and IL-2 secretion. Animal models of bacteremia have demonstrated that SEIW can increase the bacterial load in the liver [13]. Furthermore, SEIW is the only SAG predicted to be present in the epidemic clone CC398, and its deletion in CC398 abrogated its capacity to promote T cell proliferation *in vitro*, suggesting that this protein may be associated with immune recognition [13,37,38].

In this study, we analyzed the genetic distribution, amino acid polymorphisms, biological and antitumor activity, and TCR binding sites of SEIW in *S. aureus* strains prevalent in China to gain further insights into its antitumor properties and therapeutic potential.

Material and methods

Bacterial strains and culture conditions

A total of 986 *S. aureus* strains, with 831 from 16 provinces of China across 9 distinct food substrates and obtained from 6 provinces representing various hosts including healthy individuals, clinical patients, and porcine sources. These isolates exhibited broad genetic diversity, encompassing multiple sequence type (ST) profiles, *spa* polymorphisms, and clonal cluster variations. All strains of *S. aureus* are stored in our laboratory. All *S. aureus* strains were cultured on Colombia blood agar plates at 37°C for 14–16 h.

E. coli DH5α (Invitrogen, USA) was used for cloning and BL21(DE3) (Novagen) was used as the expression host. Competent *E. coli* was cultured aerobically at 37°C in Luria-broth (LB) medium containing kanamycin (25 µg/mL).

Plasmid and cell lines

The cloning vector pMD18-T was purchased from Takara Biotechnology (Dalian, China), and the expression vector pET-28a (+) was stored in our laboratory. Human gastric cancer cell line AGS, lung adenocarcinoma cancer cell line A549, and breast cancer cell line MCF-7 were obtained from the American Type Culture Collection (ATCC). Human peripheral blood mononuclear cells (PBMCs) were purchased from Saily Biotechnology Co. (Shanghai, China).

Sequence analyses

A whole-genome sequence dataset of food-derived *S. aureus* strains ($n = 831$) from China was used to examine the genetic distribution of *selw* [39,40]. The *selw* gene in these strains was identified using nucleotide BLAST (blastn) [41] with $\geq 80\%$ coverage and sequence identity. In addition, the *selw* was detected in 155 strains from patients ($n = 124$), healthy individuals ($n = 28$), and pigs ($n = 3$) in China by PCR and Sanger sequencing. The sequencing primers were synthesized by Sangon Biotech (Shanghai, China) and listed in Supplementary Table S1. Multiple sequences alignment was performed across 81 strains belonging to 54 sequence types (ST; 19 clonal complexes). A phylogenetic tree was constructed using maximum likelihood estimation with 1000 bootstrap iterations and visualized by MEGA X and iTOL (<https://itol.embl.de>) [42].

Reverse-transcription PCR (RT-PCR)

Total RNA was extracted from 13 *S. aureus* strains of different STs and origins (Supplementary Table S2) using RNAiso plus (Takara Biotechnology Corp., Dalian, China) and 1 µg of RNA was reverse transcribed into cDNA using the Primescript RT Master Kit (Takara Biotechnology Corp., Dalian, China). The *selw* gene was amplified by PCR using the primers *selw*-Fw and *selw*-Rw (Supplementary Table S1). The PCR reaction conditions were as follows: 94°C for 2 min, 35 cycles of 98°C for 10 s, 63°C for 30 s and 68°C for 30 s, followed by 72°C for 10 min.

Cloning, expression, and purification of recombinant SEIW (rSEIW)

The *selw* gene of the *S. aureus* strain DC51619 was cloned into the expression vector pET-28a (His-tag) and amplified by the primers rSEIW-F and rSEIW-R (Supplementary Table S1). rSEIW proteins with a non-cleavable N-terminal 6×His-tag were produced in *E. coli* according to previous methods [43]. *E. coli* BL21(DE3) containing the pET-28a-*selw* plasmid was cultured in LB with kanamycin and induced with a final concentration of 1 mM isopropyl-β-D-thiogalactopyranoside (IPTG) (TransGen Biotech, Beijing, China) for 12 h at 16°C during mid-exponential phase ($OD_{600} = 0.6–0.8$). Proteins were purified by affinity chromatography (AKTA fast protein liquid chromatography (FPLC) system explorer 100) on a HisTrap column (GE healthcare, Buckinghamshire, UK). Then, the protein content in the suspension was determined by the Pierce™ BCA Protein Assay (Thermo Fisher Scientific, US), while endotoxin levels were evaluated using the Pierce™ Chromogenic Endotoxin Quant Kit (Thermo Fisher Scientific, US), in strict accordance with the manufacturers' guidelines. Finally, protein purity was verified by sodium dodecyl sulfate – polyacrylamide gel electrophoresis (SDS-PAGE).

Western blot identification of SEIW

Monoclonal and polyclonal antibodies (Biodragon Immunotechnologies Co., Ltd., Beijing, China) were obtained by immunizing mice and rabbits with rSEIW, respectively. Both prepared antibodies were stored in our laboratory. Eight *S. aureus* strains were cultured in brain heart infusion broth with 200 rpm shaking at 37°C for 14–16 h. Culture supernatants were harvested by centrifugation, concentrated to 1/10th of the original volume using Amicon-Ultra-15 Centrifugal Filter units (10,000 Da MWCO) (Millipore, Merck, Germany), passed through 0.22 μm filters, and stored at –20°C. Bacterial proteins were extracted from eight *S. aureus* isolates by cell lysis, and 20 μg of lysate of each strain was separated by SDS-PAGE and transferred onto a 0.22 μm PVDF membrane (Millipore, MA, USA). The membrane was blocked with 5% skim milk powder in PBS for 2 h at room temperature, incubated with primary monoclonal antibody in blocking buffer at 4°C overnight, washed 3 times with TBST, and incubated with goat anti-mouse IgG-HRP (ZSGB-Bio, Beijing, China) for 1 h at room temperature. After washing, the membrane was incubated with ECL substrate (Takara Biotechnology Dalian, China) and the protein bands were visualized using an ultrasensitive quantitative fluorescent gel imaging system (Amersham

Imager 680, GE healthcare). Information on the test strains is detailed in Supplementary Table S2. The same procedures were followed for the detection of SEIW using primary rabbit polyclonal antibody and goat anti-rabbit secondary IgG-HRP (ZSGB-Bio, Beijing, China).

HPLC-MS/MS identification of SEIW

Bacterial proteins were extracted from the DC50005 and DC51908 strains and separated by SDS-PAGE. Protein bands with a molecular weight of 25–35 kDa were cut out from the gel and digested as described previously using rSEIW as a reference [44]. After digestion, the digested proteins were passed through a MonoSpin® C18 desalination column according to the manufacturer's instructions and dried by vacuum at 4°C. The protein samples were analyzed using HPLC-MS/MS as described previously [44] and the resulting protein data were processed with Proteome Discoverer (version 1.4).

Stability assay of rSEIW

The stability of rSEIW was evaluated as described previously [45–47] using BSA (Sigma, Germany) and rSEA (produced in our lab) as controls. To test the heat stability of rSEIW, 500 μL of 100 μg/mL rSEIW in PBS was heated in a heat block at 100°C for 0, 0.5, 1, 2, 4, 6, 8, or 10 h.

BSA, rSEA and rSEIW were digested by pepsin (Sigma-Aldrich, Germany) to assess the proteolytic stability of rSEIW. Each protein (final concentration 100 μg/mL) was incubated with pepsin (100 μg/mL in 0.1 M sodium acetate buffer, pH 4.5) in a final volume of 500 μL at 37°C for 0, 0.5, 1, 2, or 4 h [45].

Similarly, each protein (final concentration 100 μg/mL) was incubated with trypsin (Sigma-Aldrich, Germany; 50 μg/mL in 0.01 M Tris-HCl, pH 8.0) in a final volume of 500 μL at 37°C for 0, 0.5, 1, 2, 4, 6, or 8 h. The pepsin and trypsin digestion reactions were terminated by heating the samples at 95°C for 5 min, followed by immediate cooling before loading for SDS-PAGE. After electrophoresis, the gel was stained with Coomassie Brilliant Blue for protein band visualization.

In vitro antitumor activity assay

The antitumor activity of rSEIW was evaluated using human PBMCs as effector cells and MCF-7 breast cancer cells, AGS gastric cancer cells, and A549 lung cancer cells as target cells. Tumor cells (5×10^3 cells/100 μL) and human PBMCs (8×10^4 cells/100 μL) were seeded in separate 96-well flat-bottom plates and cultured in RPMI 1640 medium (Gibco, UK) with 10%

(v/v) heat-inactivated fetal bovine serum (Gibco, UK), 100 U/mL penicillin, and 100 µg/mL streptomycin at 37°C with 5% CO₂ for 24 h. Human PBMCs were treated with a final concentration of 10⁰–10^{−7} µg/mL rSEIW in a total volume of 280 µL/well and cultured at 37°C for another 24 h. Discarded the supernatant of tumor cells, the cultured human PBMCs and rSEIW mixtures were added at 280 µL/well into the tumor cell plates at a 16:1 effector: target ratio and incubated at 37°C for 72 h. Human PBMCs, tumor cells, RPMI 1640 medium, and BSA were used as negative controls. After incubation, the cells were washed three times with RPMI 1640 medium and treated with 100 µL/well of RPMI 1640 containing 10 µL of CCK-8 solution (Beyotime Biotechnology, Shanghai, China) for 2 h, followed by the measurement of optical density (OD) at 450 nm using a microplate reader (Thermo Scientific, USA). Each experiment was repeated three times, and each sample was tested in triplicate wells. The half maximal inhibitory concentration (IC₅₀) was determined by nonlinear regression analysis (curve fit) of the concentration – response curve. Tumor growth inhibition (TGI) rate was calculated by:

$$\text{TGI rate} = 100 - [(\text{OD of experimental group} - \text{OD of human PBMCs}) / (\text{OD of tumor cell control group} - \text{OD of blank group})] \times 100\%.$$

Cloning, expression, and purification of mutant SEIW-Y18A, SEIW-N19A, SEIW-W55A, SEIW-C88A, and SEIW-C98A

In our previous study, the simulation of SEIW docking on the TCR revealed five important binding sites, namely Y18, N19, W55, C88, and C98 [43]. To verify the role of these residues in mediating TCR binding, alanine mutations were introduced into the pET-28a-*selw* vector by site-directed mutagenesis and mutant SEIW were constructed by overlap extension PCR using the chromosomal DNA of *S. aureus* DC51619 as a template. All primers used are listed in Supplementary Table S1. The PCR reaction conditions were as follows: 1 cycle of 98°C for 30 s, 35 cycles of 98°C for 8 s, 55°C for 20 s and 72°C for 25 s, followed by 72°C for 10 min. The mutant proteins were confirmed by DNA sequencing and subcloned into the pET-28a expression vector. All mutant proteins were expressed in *E. coli* BL21 (DE3) cells and purified by His-Trap FF crude nickel affinity column followed by ion exchange chromatography. Protein purity was verified by SDS-PAGE. Following endotoxin removal and protein concentration determination, the samples were stored at −80°C.

T cell proliferation assays of wild-type and mutant SEIW

Human PBMCs were seeded in 96-well flat-bottom plates at 1×10⁶ cells/mL in RPMI 1640 medium containing 10% (v/v) heat-inactivated fetal bovine serum, 100 U/mL penicillin, and 100 µg/mL streptomycin, and then treated with 10-fold dilutions of wild-type (WT) or mutant proteins (1 to 10^{−5} µg/mL) for 72 h at 37°C with 5% CO₂. Human PBMCs treated with rSEA (1 to 10^{−5} µg/mL) were used as the positive control, while those treated with or without 1 µg/mL of BSA were used as the negative and blank controls, respectively. After incubation, the supernatant was removed and the cells were treated with fresh medium containing 10% CCK-8 reagent (v/v) (Beyotime Biotechnology, Shanghai, China) at 37°C for 2 h. OD₄₅₀ was measured to calculate the proliferation index (PI): PI = (OD of experimental wells – OD of blank) / (OD of negative control wells – OD of blank). The experiments were independently conducted three times, with at least three biological replicates.

Cytokine assay of WT and mutant SEIW

Human PBMCs were stimulated with rSEA and WT-rSEIW and mutant rSEIW as described above. Cell culture supernatants were collected for the detection of IL-2, IFN-γ, and TNF-α using ELISA kits (Invitrogen, USA) according to the manufacturer's instructions. OD₄₅₀ was measured using a microplate reader. Each sample was tested in triplicate wells and each experiment was repeated three times.

Statistical analysis

Data were statistically analyzed using one-way ANOVA in Origin 2017 (USA) and graphs were generated using Adobe Illustrator CS5 (USA). Data are expressed as mean ± standard deviation (mean ± SD). *p* < 0.05 was considered as statistically significant.

Results

Genetic distribution and sequence polymorphisms of SEIW

The *selw* gene was identified in all 986 (100%) *S. aureus* strains examined and was prevalent among the endemic clonal lineages CC1, CC5, CC6, CC7, CC8, CC9, CC22, CC25, CC45, CC59, CC72, CC121, and CC398.

Sequence comparisons of 81 strains from 54 STs (19 clonal complexes) showed a less conserved N-terminus compared to the C-terminus, with a 90.5% amino acid

sequence identity (Supplementary Figure S1). Phylogenetic analysis of the SEIW amino acid sequences revealed 19 distinct subtypes, including subtype 5 (25.9%, 21/81), subtype 8 (11.1%, 9/81), subtype 9 (11.1%, 9/81), subtype 3 (8.6%, 7/81), subtype 7 (6.2%, 5/81), and subtype 10 (6.2%, 5/81). Full-length, intact *selw* variants were identified in 56 (69.1%) strains across 14 clonal complexes, while truncated *selw* caused by premature stop codons at base 110 or 139 were detected in the remaining 25 (30.9%) strains across 7 clonal complexes, with most belonging to subtype 5 (25.9%, 21/81), followed by subtype 13 (2.5%, 2/81), subtype 19 (1.2%, 1/81), and subtype 16 (1.2%, 1/81). Intact and truncated *selw* alleles were present in both human and animal *S. aureus* strains. Additionally, truncated *selw* alleles were predominantly found in clones CC5, CC6, CC7, CC9, CC30, CC72, and CC188 (Figure 1).

SEIW transcript and protein expression

selw transcripts (241 bp) were amplified by RT-PCR in 13 strains from 6 clonal complexes (Supplementary Figure S2A). HPLC-MS/MS analysis of SEIW proteins in 2 of the 13 strains revealed 9 peptide matches (45% coverage) between strain DC51908 and rSEIW, and 6 peptide matches between strain DC50005 and rSEIW (32% coverage) (Table 1).

SEIW expression in eight *S. aureus* isolates was also detected by Western blot (WB) using rabbit polyclonal and mouse monoclonal antibodies, which have been confirmed to specifically react with rSEIW but not rSEA (Supplementary Figure S2B, C). WB with the mouse monoclonal antibody showed that SEIW was present in the bacterial proteins but absent from the culture supernatant of the eight isolates (Figure 2(A)). Furthermore, WB with the rabbit polyclonal antibody detected SEIW in the bacterial proteins of two isolates and in the culture supernatant of one isolate (Figure 2(B)).

Stability of rSEIW

The heat stability test showed that rSEIW was degraded after heating at 100°C for 4 h, whereas rSEA was completely degraded after 8 h, and the control BSA was fully degraded after just 1 h (Figure 3(A)). The digestion tolerance test with pepsin demonstrated that both rSEIW and BSA were degraded within 0.5 h, whereas rSEA remained stable for 4 h (Figure 3(B)). Similarly, rSEIW and BSA were degraded by trypsin after 0.5 h, while rSEA remained intact at 8 h post-digestion (Figure 3(C)).

In vitro antitumor activity of rSEIW

The inhibitory effects of rSEIW-activated PBMCs on MCF-7, AGS, and A549 cell proliferation were examined using the CCK-8 assay. As shown in Figure 4 and Supplementary Figure S3, rSEIW significantly inhibited MCF-7 and AGS cell proliferation *in vitro* ($p < 0.05$) compared with the negative control. The rate of PBMC-mediated MCF-7 and AGS cell inhibition increased in a dose-dependent manner as rSEIW concentration increased, achieving 80% TGI rate at a concentration of 10^{-4} µg/mL and IC_{50} of 1.9×10^{-5} µg/mL and 8.1×10^{-5} µg/mL, respectively. On the other hand, rSEIW marginally inhibited A549 cell growth (IC_{50} of 1878 µg/mL) compared to those observed in MCF-7 and AGS cells.

Superantigenic activity of rSEIW mutants

The SEIW mutants Y18A, N19A, W55A, C88A, and C98A were cloned into pET-28a vectors and subsequently expressed and purified from *E. coli* BL21(D3) (Supplementary Figure S4A–C). The superantigenic activities of these mutants were assessed using PBMC proliferation and cytokine production assays. First, the mitogenic effect of the five rSEIW mutants on human PBMCs was evaluated by the CCK-8 assay using rSEIW and rSEA as controls (Figure 5(A)). Notably, the C88A and C98A mutants showed significantly lower mitogenic activity on human PBMCs at the concentration of 10^0 – 10^{-4} µg/mL compared with WT-rSEIW ($p < 0.001$). The proliferative capacity of PBMCs stimulated by N19A was also reduced, but the difference was not statistically significant. In contrast, Y18A and W55A exhibited marginally higher mitogenic activities on human PBMCs compared with rSEIW ($p > 0.05$).

Next, we further examined IL-2, IFN-γ and TNF-α production from PBMCs treated with different concentrations of rSEA, rSEIW and the C88A and C98A mutants. Similar to the findings from the proliferation assay, IL-2, IFN-γ and TNF-α productions were significantly lower from C98A-stimulated PBMCs compared to rSEIW-stimulated PBMCs at 10^0 – 10^{-5} µg/mL ($p < 0.0001$). On the other hand, C88A significantly downregulated IFN-γ and TNF-α expression at 10^0 – 10^{-5} µg/mL and inhibited IL-2 secretion at 10^{-1} – 10^{-5} µg/mL but not at 10^0 µg/mL. Taken together, these data suggested that the C98 and C88 residues are critical for TCR binding by SEIW (Figure 5(B–D)).

Discussion

Our study demonstrated that the *selw* gene is present in all 986 tested *S. aureus* strains from various sources in




Figure 1. Phylogenetic analysis of SEIW amino acid sequences by maximum-likelihood estimation. The tree was generated using the iTOL online platform (<https://itol.embl.de/>). The outer, middle, and inner rings represent the source, CC, and subtypes of SEIW, respectively. CC, clonal complexes.

Table 1. Identification of SEIW from *S. aureus* strains by HPLC-MS/MS.

Accession	Description	Length of protein (AAs)	MW [kDa]	Cal. pI	Coverage [%]	Peptides	Unique Peptides	PSMs	Score Sequest HT: Sequest HT	Peptides (by Search Engine): Sequest HT
rSEIW	SEIW	222	26.1	6.29	55	20	20	188	536.48	20
DC51908	SEIW	222	26.1	6.29	45	9	9	14	45.66	9
DC50005	SEIW	222	26.1	6.29	32	6	6	8	23.03	6

Abbreviations: AA, amino acids; Cal. pI, calculated isoelectric point; MW, molecular weight; PSM, peptide spectrum match.

China and is widely distributed across 13 endemic clonal lineages, which is in agreement with findings reported in other countries [13,34,48]. Additionally, sequence comparisons revealed that polymorphisms in SEIW were predominantly located in the N-terminus of the protein. Vrieling et al. demonstrated that different

SEIW allelic variants exhibit distinct superantigenic activity and V β T cell activation, independent of the *S. aureus* host species. Notably, two SEIW variants were found to strongly activate human V β 21 T cells [13]. Whether this finding applies to the dominant SEIW variants in different clone complexes in China requires






Figure 2. SEIW protein expression in *S. aureus* strains detected by WB. (A) SEIW protein detection using mouse monoclonal antibody; (B) SEIW protein detection using rabbit polyclonal antibody. Numbers 1–8: different *S. aureus* strains; rSEIW: positive control; M: Marker.

A. 100°C



B. Pepsin



C. Trypsin




Figure 3. Heat and proteolytic stability of rSEIW. (A) Heat stability of rSEIW. 100 μ g/mL of BSA, rSEA, and rSEIW were heated at 100°C for the indicated time and analyzed by SDS-PAGE. (B) Pepsin stability of rSEIW. 100 μ g/mL of BSA, rSEA, and rSEIW were treated with pepsin (100 μ g/mL) at 37°C for the indicated time at pH 4.5. (C) Trypsin stability of rSEIW. 100 μ g/mL of BSA, rSEA, and rSEIW were treated with trypsin (50 μ g/mL) at 37°C for the indicated time at pH 8.0. M: Marker. P: Pepsin; t: trypsin.




Figure 4. Inhibition of tumor cell growth by rSEIW *in vitro*. PBMCs stimulated with 10^0 to 10^{-6} $\mu\text{g/mL}$ of rSEIW were co-cultured with (A) MCF-7, (B) AGS, or (C) A549 cells at an effector to target cell ratio of 16:1 for 72 h. BSA and untreated cells were used as negative controls. The data represent the mean $\pm$ SD of three independent experiments. * $p < 0.05$.




Figure 5. Proliferative capacity of human PBMCs and their cytokine secretion profiles after stimulation with different concentrations of rSEA, rSEIW, and Y18A, N19A, W55A, C88A, C98A mutants. (A) PBMCs were treated with rSEA, rSEIW or mutant proteins for 72 h; (B, C, D) ELISA detection of IL-2, IFN- γ and TNF- α levels from PBMCs stimulated with different concentrations of rSEA, rSEIW, C88A, and C98A. Untreated PBMCs and PBMCs treated with BSA were used as negative controls. Data represent the mean $\pm$ SD of three independent experiments. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$, NS: not significant.

further investigation. Additionally, our data indicated a higher percentage of *S. aureus* strains harboring a full-length, intact *selw* gene variant compared to that reported by Vrieling et al. (69.1% vs. 62.5%) [13], which may be attributed to differences in sample selection.

We observed that several dominant *S. aureus* strains in China transcribed and expressed the *selw* gene. However, SEIW protein levels were notably low in the culture supernatant, potentially due to either minimal protein expression at the time of collection or the lack of protein secretion under the current culture conditions.

The presence of SE genes on various genetic elements contributes to the complexity and diversity of their expression. Several studies demonstrated that the elements Agr, σ B, Rot, several Sar homologs, SaeR, and phage life cycle played a role in the regulation of SE expression [49–52]. Furthermore, environmental conditions such as temperature, food types, salt content, water activity, pH, and competing strains further modulated SE expression [50,53]. SEIW is a core genome-encoded SAg [13,33], but its regulatory mechanism remains unclear. Thus, further studies are warranted to elucidate the regulatory mechanisms and the various environmental conditions affecting SEIW expression.

Several SEs have been shown to be resistant to heat and digestive enzymes, contributing to food contamination and gastrointestinal infections [24,54,55]. Our results demonstrated that SEIW exhibited heat resistance comparable to that of SEA, indicating that SEIW can withstand degradation by conventional cooking methods. However, SEIW was susceptible to pepsin and trypsin digestion, implying that the protein is degraded upon entry into the gastrointestinal tract and therefore unlikely to induce emesis.

As a member of the SE family, SEC2 has been extensively used as a clinical tumor immunotherapeutic agent in China for over two decades [56]. However, the widespread application of enterotoxins has been constrained by their toxic side effects, which can be addressed by utilizing enterotoxin-like proteins with minimal or absent emetic activity, making them promising candidates for clinical drug development [14]. In this study, we found that rSEIW strongly inhibited MCF-7 and AGS cell proliferation, achieving a TGI rate of 80% at a concentration of 10^{-4} μ g/mL, which is comparable to those of other enterotoxins, such as SEA, SEB, and SEQ [20,57–60]. The antitumor activities of SEs are predominantly driven by cell-mediated immunity, particularly through immune responses induced by cytotoxic T cells [61,62]. In tumor tissues, CD8⁺ T cells are activated through TCR recognition of tumor antigens presented by MHC class I molecules on tumor cells [63]. Moreover, SEs mutants have been shown to enhance the tumor immune microenvironment, suggesting their potential as a strategy to boost immune responses. Notably, SEIW lacks the emetic activity that is characteristic of other enterotoxins (unpublished data). This unique property, combined with its observed antitumor potential, underscores its promise for both mechanistic research and clinical applications. Therefore, characterizing the *in vivo* antitumor mechanisms and activities of rSEIW and SEIW mutants will be the focus of future research.

In our previous work, molecular docking simulations of SEIW with the TCR revealed five putative TCR binding sites, namely Y18, N19, W55, C88, and C98 [43]. To evaluate the role of these sites in mediating TCR binding, SEIW Y18A, N19A, W55A, C88A, and C98A mutants were constructed by site-directed mutagenesis. It has been shown that SEB and SEA interact with TCRV β through distinct residues within the shallow groove between the β -barrel and α_2 -helix at the N-terminus [64,65]. Rödström et al. identified a common hot spot asparagine residue within the α_2 -helix of five SEs (SEA N25, SEB N23, SEC N23, SEE N21, and SEH N16) that played a significant role in SAg-TCR complex formation and binding energy [65]. In contrast, the same residue (N19) in SEIW had no significant impact on SEIW-TCR complex formation ($p > 0.05$). Our result showed that C98 and C88 were the key residues affecting the superantigenic activity of SEIW, as mutations at both residues significantly attenuated PBMC proliferation and IL-2, IFN- γ and TNF- α production. SEIW C98/C88, which corresponds to SEA C106/C96, SEB C113/C93, SEC2 C110/C93, SED C106/C96, and SEE C106/C96, are conserved sites in the SEs sequence found within the disulfide loop of the β -grasp domain at the C-terminus of SEIW [66–70]. This disulfide loop is a highly conserved structural feature among all SEs and is critical for the stability, structure, and biological functions of enterotoxins [71–74]. Mutations at SEC2 C110/C93 and SEA C106/C96 abolished their ability to promote murine T cell proliferation and cytotoxicity *in vitro*, suggesting that the cysteine residues in the disulfide loop are essential for the superantigenic functions of SEC2 and SEA [70,75]. Similarly, we showed for the first time that the C98/C88 residues in the β -grasp disulfide loop are critical for the superantigenicity of SEIW. Additionally, the SEIW C98A mutant resulted in significantly greater inhibition of cytokine production compared to the C88A mutant, suggesting that the superantigenic activity of SEIW is predominantly contributed by C98. This contrasts with the finding on SEC2, where C93, rather than C110, plays a more critical role in its superantigenic activity [70]. This inconsistency may be attributed to subtle differences in protein structures and proximity to the MHC II binding sites. Since C93 is closer to both the TCR and MHC II binding sites in SEC2, a mutation at C93 could lead to a more pronounced impairment of T cell response than a mutation at C110 [76,77]. Furthermore, it would be worthwhile to investigate whether simultaneous mutations at both the C88 and C98 sites could further diminish the binding affinity between SEIW and TCR, potentially impacting the synergistic effect on T cell mitotic activity.

In conclusion, we found that the *selw* gene is broadly distributed among the endemic clonal lineages of

S. aureus. SEIW is resistant to heat but susceptible to enzymatic digestion. Our study is the first to demonstrate that the C98 and C88 residues in the disulfide loop of the β -grasp domain are essential for the superantigenic functions of SEIW. Altogether, these findings offer valuable insights to the pathogenesis of *S. aureus* and highlight its potential as a novel therapeutic target for *S. aureus* infections. Additionally, the antitumor activity of SEIW observed *in vitro* underscore its promise for both mechanistic studies and clinical research.

Acknowledgements

We thank the faculty, staff and students of this research group who contributed to the analysis of the data in this study.

Conceptualization: X.Y., J.Z., and D.H.; Methodology: X.Y., J.Z., Y.Y., X.W., F.M., and Yanan Gong; Resource: X.Y., and J.Z.; Investigation: X.Y., Y.Y., Yahui Guo, L.L., J.F., Y.Z., W.W., D.X., L.W., M.Z., and D.H.; Data curation: X.Y., and Y.Y.; Writing original draft: Y.Y.; Manuscript review and editing: all authors; Visualization: X.Y.; Project administration: X.Y.; Supervision: X.Y., J.Z., Y.Y., and X.W.; Funding acquisition: X.Y. All authors contributed to critical revision of the manuscript and approved the final version for submission.

Author contributions

CRedit: **Yuhua Yang**: Data curation, Investigation, Methodology, Supervision, Writing – original draft, Writing – review & editing; **Xiaoyue Wei**: Methodology, Supervision, Writing – review & editing; **Fanliang Meng**: Methodology, Writing – review & editing; **Yanan Gong**: Methodology, Writing – review & editing; **Yahui Guo**: Investigation, Writing – review & editing; **Lijin Long**: Investigation, Writing – review & editing; **Jiaming Fan**: Investigation, Writing – review & editing; **Yakun Zhao**: Investigation, Writing – review & editing; **Wanting Wang**: Investigation, Writing – review & editing; **Di Xiao**: Investigation, Writing – review & editing; **Lei Wang**: Investigation, Writing – review & editing; **Maojun Zhang**: Investigation, Writing – review & editing; **Dongliang Hu**: Conceptualization, Investigation, Writing – review & editing; **Jianzhong Zhang**: Conceptualization, Methodology, Resources, Supervision, Writing – review & editing; **Xiaomei Yan**: Conceptualization, Data curation, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Visualization, Writing – review & editing.

Funding

This work was supported by the National Natural Science Foundation of China [81873959], Capital's Funds for Health Improvement and Research [2024-2-G-4363], and Financial Special Fund [102393240020020000003].

Disclosure statement

No potential conflict of interest was reported by the author(s).

Data availability statement

The data that support the findings of this study are openly available in Figshare at

<https://doi.org/10.6084/m9.figshare.28440671.v1>.

Ethics statement

This study is a laboratory-based retrospective research approved by the Ethics Committee of National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention and Prevention (Approval No.: ICDC-2023003). All human-derived *S. aureus* strains were collected from routine cultures of residual samples used in clinical diagnosis, and the clinical data were obtained from patient electronic medical records; however, patient personal information was anonymized. And this study strictly adhered to the principles of the Declaration of Helsinki. Therefore, the requirement for informed consent was waived according to the national guideline for the *Measures for the Ethical Review of Life Sciences and Medical Research Involving Human Subjects* issued in 2023. Given that nasal swab sampling causes negligible harm to pigs, we secured verbal consent from the farm owner before commencing collection. This procedure was reviewed and approved by the National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention and the Laboratory Animal Welfare & Ethics Committee (Approval number: 2016–010). Other all animal experiments were approved by the National Institute for Communicable Disease Control and Prevention, Chinese Center for Disease Control and Prevention and Laboratory Animal Welfare & Ethics Committee (Approval number: 2018–002).

ORCID

Di Xiao  <http://orcid.org/0000-0002-5964-5925>

Jianzhong Zhang  <http://orcid.org/0000-0001-7056-8206>

Xiaomei Yan  <http://orcid.org/0000-0002-4532-6878>

References

- [1] Laux C, Peschel A, Krismer B, et al. *Staphylococcus aureus* colonization of the human nose and interaction with other microbiome members. *Microbiol spectr*. 2019;7(2). doi: [10.1128/microbiolspec.GPP3-0029-2018](https://doi.org/10.1128/microbiolspec.GPP3-0029-2018)
- [2] Verhoeven PO, Gagnaire J, Botelho-Nevers E, et al. Detection and clinical relevance of *Staphylococcus aureus* nasal carriage: an update. *Expert Rev Anti Infect Ther*. 2014;12(1):75–89. doi: [10.1586/14787210.2014.859985](https://doi.org/10.1586/14787210.2014.859985)
- [3] Gagnaire J, Verhoeven PO, Grattard F, et al. Epidemiology and clinical relevance of *Staphylococcus aureus* intestinal carriage: a systematic review and meta-analysis. *Expert Rev Anti Infect Ther*. 2017;15(8):767–785. doi: [10.1080/14787210.2017.1358611](https://doi.org/10.1080/14787210.2017.1358611)

- [4] Lowy FD. *Staphylococcus aureus* infections. N Engl J Med. 1998;339(8):520–532. doi: [10.1056/nejm199808203390806](https://doi.org/10.1056/nejm199808203390806)
- [5] Hanawa T, Shimoda-Komatsu Y, Araki K, et al. Skin and soft tissue infections caused by different genotypes of PVL-positive community-acquired methicillin-resistant *Staphylococcus aureus* strains. Jpn J Infect Dis. 2020;73(1):72–75. doi: [10.7883/yoken.JJID.2019.162](https://doi.org/10.7883/yoken.JJID.2019.162)
- [6] Kwiecinski JM, Horswill AR. *Staphylococcus aureus* bloodstream infections: pathogenesis and regulatory mechanisms. Curr Opin microbiol. 2020;53:51–60. doi: [10.1016/j.mib.2020.02.005](https://doi.org/10.1016/j.mib.2020.02.005)
- [7] Etter D, Schelin J, Schuppler M, et al. Staphylococcal enterotoxin C—an update on SEC variants, their structure and properties, and their role in foodborne intoxications. Toxins (Basel). 2020;12(9):584. doi: [10.3390/toxins12090584](https://doi.org/10.3390/toxins12090584)
- [8] Benkerroum N. Staphylococcal enterotoxins and enterotoxin-like toxins with special reference to dairy products: an overview. Crit Rev Food Sci Nutr. 2018;58(12):1943–1970. doi: [10.1080/10408398.2017.1289149](https://doi.org/10.1080/10408398.2017.1289149)
- [9] Lina G, Bohach GA, Nair SP, et al. Standard nomenclature for the superantigens expressed by *Staphylococcus*. J Infect Dis. 2004;189(12):2334–2336. doi: [10.1086/420852](https://doi.org/10.1086/420852)
- [10] Xu SX, McCormick JK. Staphylococcal superantigens in colonization and disease. Front Cell Infect microbiol. 2012;2:52. doi: [10.3389/fcimb.2012.00052](https://doi.org/10.3389/fcimb.2012.00052)
- [11] Pumphrey N, Vuidepot A, Jakobsen B, et al. Cutting edge: evidence of direct TCR alpha-chain interaction with superantigen. J Immunol. 2007;179(5):2700–2704. doi: [10.4049/jimmunol.179.5.2700](https://doi.org/10.4049/jimmunol.179.5.2700)
- [12] Kappler J, Kotzin B, Herron L, et al. V β -specific stimulation of human T cells by staphylococcal toxins. Science. 1989;244(4906):811–813. doi: [10.1126/science.2524876](https://doi.org/10.1126/science.2524876)
- [13] Vrieling M, Tuffs SW, Yebra G, et al. Population analysis of *staphylococcus aureus* reveals a cryptic, highly prevalent Superantigen SEIW that contributes to the pathogenesis of bacteremia. MBio. 2020;11(5). doi: [10.1128/mBio.02082-20](https://doi.org/10.1128/mBio.02082-20)
- [14] Fraser JD, Proft T. The bacterial superantigen and superantigen-like proteins. Immunol Rev. 2008;225(1):226–243. doi: [10.1111/j.1600-065X.2008.00681.x](https://doi.org/10.1111/j.1600-065X.2008.00681.x)
- [15] Krakauer T. Staphylococcal superantigens: pyrogenic toxins induce toxic shock. Toxins (Basel). 2019;11(3):178. doi: [10.3390/toxins11030178](https://doi.org/10.3390/toxins11030178)
- [16] Balaban N, Rasooly A. Staphylococcal enterotoxins. Int J Food microbiol. 2000;61(1):1–10. doi: [10.1016/s0168-1605\(00\)00377-9](https://doi.org/10.1016/s0168-1605(00)00377-9)
- [17] Munson SH, Tremaine MT, Betley MJ, et al. Identification and characterization of staphylococcal enterotoxin types G and I from *staphylococcus aureus*. Infect Immun. 1998;66(7):3337–3348. doi: [10.1128/iai.66.7.3337-3348.1998](https://doi.org/10.1128/iai.66.7.3337-3348.1998)
- [18] Su YC, Wong AC. Identification and purification of a new staphylococcal enterotoxin, H. Appl Environ microbiol. 1995;61(4):1438–1443. doi: [10.1128/aem.61.4.1438-1443.1995](https://doi.org/10.1128/aem.61.4.1438-1443.1995)
- [19] Ono HK, Hirose S, Naito I, et al. The emetic activity of staphylococcal enterotoxins, SEK, SEL, SEM, SEN and SEO in a small emetic animal model, the house musk shrew. Microbiol Immunol. 2017;61(1):12–16. doi: [10.1111/1348-0421.12460](https://doi.org/10.1111/1348-0421.12460)
- [20] Omoe K, Hu DL, Ono HK, et al. Emetic potentials of newly identified staphylococcal enterotoxin-like toxins. Infect Immun. 2013;81(10):3627–3631. doi: [10.1128/iai.00550-13](https://doi.org/10.1128/iai.00550-13)
- [21] Omoe K, Hu DL, Takahashi-Omoe H, et al. Identification and characterization of a new staphylococcal enterotoxin-related putative toxin encoded by two kinds of plasmids. Infect Immun. 2003;71(10):6088–6094. doi: [10.1128/iai.71.10.6088-6094.2003](https://doi.org/10.1128/iai.71.10.6088-6094.2003)
- [22] Sato'o Y, Omoe K, Aikawa Y, et al. Investigation of *staphylococcus aureus* positive for staphylococcal enterotoxin S and T genes. J Vet Med Sci. 2021;83(7):1120–1127. doi: [10.1292/jvms.20-0662](https://doi.org/10.1292/jvms.20-0662)
- [23] Ono HK, Hirose S, Narita K, et al. Histamine release from intestinal mast cells induced by staphylococcal enterotoxin A (SEA) evokes vomiting reflex in common marmoset. PLOS Pathog. 2019;15(5):e1007803. doi: [10.1371/journal.ppat.1007803](https://doi.org/10.1371/journal.ppat.1007803)
- [24] Suzuki Y, Ono HK, Shimojima Y, et al. A novel staphylococcal enterotoxin SE02 involved in a staphylococcal food poisoning outbreak that occurred in Tokyo in 2004. Food microbiol. 2020;92:103588. doi: [10.1016/j.fm.2020.103588](https://doi.org/10.1016/j.fm.2020.103588)
- [25] Zhang DF, Yang XY, Zhang J, et al. Identification and characterization of two novel superantigens among *Staphylococcus aureus* complex. Int J Med microbiol. 2018;308(4):438–446. doi: [10.1016/j.ijmm.2018.03.002](https://doi.org/10.1016/j.ijmm.2018.03.002)
- [26] Wilson GJ, Seo KS, Cartwright RA, et al. A novel core genome-encoded superantigen contributes to lethality of community-associated MRSA necrotizing pneumonia. PLoS Pathog. 2011;7(10):e1002271. doi: [10.1371/journal.ppat.1002271](https://doi.org/10.1371/journal.ppat.1002271)
- [27] Tuffs SW, Haeryfar SMM, McCormick JK. Manipulation of innate and adaptive immunity by staphylococcal superantigens. Pathogens. 2018;7(2):53. doi: [10.3390/pathogens7020053](https://doi.org/10.3390/pathogens7020053)
- [28] Thomas D, Chou S, Dauwalder O, et al. Diversity in *staphylococcus aureus* enterotoxins. Chem Immunol Allergy. 2007;93:24–41. doi: [10.1159/000100856](https://doi.org/10.1159/000100856)
- [29] Belfrage H, Dohlsten M, Hedlund G, et al. Enhanced and prolonged efficacy of superantigen-induced cytotoxic T lymphocyte activity by interleukin-2 in vivo. Cancer Immunol immunother. 1995;41(2):87–94. doi: [10.1007/bf01527404](https://doi.org/10.1007/bf01527404)
- [30] Zhao W, Li Y, Liu W, et al. Transcytosis, antitumor activity and toxicity of staphylococcal enterotoxin C2 as an oral administration protein drug. Toxins (Basel). 2016;8(6):185. doi: [10.3390/toxins8060185](https://doi.org/10.3390/toxins8060185)
- [31] Sun HY, Xue Q, Pan YQ, et al. Preparation and application of antibody against staphylococcal enterotoxin C2. Yao Xue Xue Bao. 2008;43(8):801–805.
- [32] Forsberg G, Ohlsson L, Brodin T, et al. Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen. Br J Cancer. 2001;85(1):129–136. doi: [10.1054/bjoc.2001.1891](https://doi.org/10.1054/bjoc.2001.1891)
- [33] Okumura K, Shimomura Y, Murayama SY, et al. Evolutionary paths of streptococcal and staphylococcal superantigens. BMC Genomics. 2012;13:404. doi: [10.1186/1471-2164-13-404](https://doi.org/10.1186/1471-2164-13-404)

- [34] Aung MS, Urushibara N, Kawaguchiya M, et al. Prevalence and genetic diversity of staphylococcal enterotoxin (-like) genes *sey*, *selw*, *selx*, *selz*, *sel26* and *sel27* in community-acquired methicillin-resistant *staphylococcus aureus*. *Toxins* (Basel). 2020;12(5):347. doi: 10.3390/toxins12050347
- [35] Wilson GJ, Tuffs SW, Wee BA, et al. Bovine *staphylococcus aureus* superantigens stimulate the entire T cell repertoire of cattle. *Infect Immun*. 2018;86(11). doi: 10.1128/iai.00505-18
- [36] Roetzer A, Haller G, Beyerly J, et al. Genotypic and phenotypic analysis of clinical isolates of *staphylococcus aureus* revealed production patterns and hemolytic potentials unlinked to gene profiles and source. *BMC microbiol*. 2016;16:13. doi: 10.1186/s12866-016-0630-x
- [37] Uhlemann AC, Porcella SF, Trivedi S, et al. Identification of a highly transmissible animal-independent *Staphylococcus aureus* ST398 clone with distinct genomic and cell adhesion properties. *MBio*. 2012;3(2). doi: 10.1128/mBio.00027-12
- [38] Uhlemann AC, McAdam PR, Sullivan SB, et al. Evolutionary dynamics of pandemic methicillin-sensitive *staphylococcus aureus* ST398 and its international spread via routes of human migration. *MBio*. 2017;8(1). doi: 10.1128/mBio.01375-16
- [39] Guo Y, Yu X, Wang J, et al. A food poisoning caused by ST7 *staphylococcal aureus* harboring sea gene in Hainan Province, China. *Front microbiol*. 2023;14:1110720. doi: 10.3389/fmicb.2023.1110720
- [40] Guo YH, He ZL, Ji QL, et al. Population structure of food-borne *Staphylococcus aureus* in China. *Zhonghua Liu Xing Bing Xue Za Zhi*. 2023;44(6):982–989. doi: 10.3760/cma.j.cn112338-20221206-01043
- [41] Camacho C, Coulouris G, Avagyan V, et al. Blast+: architecture and applications. *BMC Bioinf*. 2009;10:421. doi: 10.1186/1471-2105-10-421
- [42] Letunic I, Bork P. Interactive tree of life (iTOL) v4: recent updates and new developments. *Nucleic Acids Res*. 2019;47(W1):W256–w259. doi: 10.1093/nar/gkz239
- [43] Yang YH, Ku X, Gong YN, et al. Prediction of super-antigen active sites and clonal expression of staphylococcal enterotoxin-like W. *Zhonghua Liu Xing Bing Xue Za Zhi*. 2023;44(4):629–635. doi: 10.3760/cma.j.cn112338-20220822-00725
- [44] Zhai K, Gong Y, Sun L, et al. Dna starvation/stationary phase protection protein of *Helicobacter pylori* as a potential immunodominant antigen for infection detection. *Helicobacter*. 2023;28(2):e12955. doi: 10.1111/hel.12955
- [45] Li SJ, Hu DL, Maina EK, et al. Superantigenic activity of toxic shock syndrome toxin-1 is resistant to heating and digestive enzymes. *J Appl microbiol*. 2011;110(3):729–736. doi: 10.1111/j.1365-2672.2010.04927.x
- [46] Ono HK, Sato'o Y, Narita K, et al. Identification and characterization of a novel staphylococcal emetic toxin. *Appl Environ microbiol*. 2015;81(20):7034–7040. doi: 10.1128/aem.01873-15
- [47] Chi YI, Sadler I, Jablonski LM, et al. Zinc-mediated dimerization and its effect on activity and conformation of staphylococcal enterotoxin type C. *J Biol Chem*. 2002;277(25):22839–22846. doi: 10.1074/jbc.M201932200
- [48] Zhang P, Liu X, Zhang M, et al. Prevalence, antimicrobial resistance, and molecular characteristics of *staphylococcus aureus* and methicillin-resistant *staphylococcus aureus* from retail ice cream in Shaanxi Province, China. *Foodborne Pathog Dis*. 2022;19(3):217–225. doi: 10.1089/fpd.2021.0069
- [49] Schelin J, Wallin-Carlquist N, Cohn MT, et al. The formation of *staphylococcus aureus* enterotoxin in food environments and advances in risk assessment. *Virulence*. 2011;2(6):580–592. doi: 10.4161/viru.2.6.18122
- [50] Zeaki N, Johler S, Skandamis PN, et al. The role of regulatory mechanisms and environmental parameters in staphylococcal food poisoning and resulting challenges to risk assessment. *Front microbiol*. 2019;10:1307. doi: 10.3389/fmicb.2019.01307
- [51] Sato'o Y, Hisatsune J, Nagasako Y, et al. Positive regulation of staphylococcal enterotoxin H by rot (repressor of toxin) protein and its importance in clonal complex 81 subtype 1 lineage-related food poisoning. *Appl Environ microbiol*. 2015;81(22):7782–7790. doi: 10.1128/aem.01936-15
- [52] Cao R, Zeaki N, Wallin-Carlquist N, et al. Elevated enterotoxin A expression and formation in *Staphylococcus aureus* and its association with prophage induction. *Appl Environ microbiol*. 2012;78(14):4942–4948. doi: 10.1128/aem.00803-12
- [53] Li HN, Kang ZD, Wang T, et al. Effect of environmental factors on expression of staphylococcal enterotoxin genes. *Environ Sci Pollut Res Int*. 2023;30(50):108694–108705. doi: 10.1007/s11356-023-29412-w
- [54] Hu DL, Nakane A. Mechanisms of staphylococcal enterotoxin-induced emesis. *Eur J Pharmacol*. 2014;722:95–107. doi: 10.1016/j.ejphar.2013.08.050
- [55] Hu DL, Ono HK, Isayama S, et al. Biological characteristics of staphylococcal enterotoxin Q and its potential risk for food poisoning. *J Appl microbiol*. 2017;122(6):1672–1679. doi: 10.1111/jam.13462
- [56] Liu Y, Xu M, Su Z, et al. Increased T-cell stimulating activity by mutated SEC2 correlates with its improved antitumor potency. *Lett Appl microbiol*. 2012;55(5):362–369. doi: 10.1111/j.1472-765X.2012.03303.x
- [57] He Y, Sun Y, Ren Y, et al. The T cell activating properties and antitumor activity of staphylococcal enterotoxin-like Q. *Med Microbiol Immunol*. 2019;208(6):781–792. doi: 10.1007/s00430-019-00614-9
- [58] Yu J, Tian R, Xiu B, et al. Antitumor activity of T cells generated from lymph nodes draining the SEA-expressing murine B16 melanoma and secondarily activated with dendritic cells. *Int J Biol Sci*. 2009;5(2):135–146. doi: 10.7150/ijbs.5.135
- [59] Liu X, Zeng L, Zhao Z, et al. Pbm activation via the ERK and STAT signaling pathways enhances the anti-tumor activity of staphylococcal enterotoxin A. *Mol Cell biochem*. 2017;434(1–2):75–87. doi: 10.1007/s11010-017-3038-5
- [60] Perabo FG, Willert PL, Wirger A, et al. Preclinical evaluation of superantigen (staphylococcal enterotoxin B) in the intravesical immunotherapy of superficial bladder cancer. *Int J Cancer*. 2005;115(4):591–598. doi: 10.1002/ijc.20941

- [61] Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. *Cell Mol Immunol.* 2020;17(8):807–821. doi: [10.1038/s41423-020-0488-6](https://doi.org/10.1038/s41423-020-0488-6)
- [62] Yang Z, Bian M, Lv L, et al. Tumor-targeting NHC-Au(I) complex induces immunogenic cell death in hepatocellular carcinoma. *J Med Chem.* 2023;66(6):3934–3952. doi: [10.1021/acs.jmedchem.2c01798](https://doi.org/10.1021/acs.jmedchem.2c01798)
- [63] Veatch JR, Lee SM, Shasha C, et al. Neoantigen-specific CD4+ T cells in human melanoma have diverse differentiation states and correlate with CD8+ T cell, macrophage, and B cell function. *Cancer Cell.* 2022;40(4):393–409.e9. doi: [10.1016/j.ccell.2022.03.006](https://doi.org/10.1016/j.ccell.2022.03.006)
- [64] Li H, Llera A, Tsuchiya D, et al. Three-dimensional structure of the complex between a T cell receptor beta chain and the superantigen staphylococcal enterotoxin B. *Immunity.* 1998;9(6):807–816. doi: [10.1016/s1074-7613\(00\)80646-9](https://doi.org/10.1016/s1074-7613(00)80646-9)
- [65] Rödström KEJ, Regenthal P, Bahl C, et al. Two common structural motifs for TCR recognition by staphylococcal enterotoxins. *Sci Rep.* 2016;6:25796. doi: [10.1038/srep25796](https://doi.org/10.1038/srep25796)
- [66] Li Y, Zhu X, Huang Y, et al. Mutational analysis of the binding of staphylococcal enterotoxin D to the T cell receptor Vbeta chain and major histocompatibility complex class II. *Immunol Lett.* 2006;105(1):55–60. doi: [10.1016/j.imlet.2005.12.005](https://doi.org/10.1016/j.imlet.2005.12.005)
- [67] Leder L, Llera A, Lavoie PM, et al. A mutational analysis of the binding of staphylococcal enterotoxins B and C3 to the T cell receptor β chain and major histocompatibility complex class II. *J Exp Med.* 1998;187(6):823–833. doi: [10.1084/jem.187.6.823](https://doi.org/10.1084/jem.187.6.823)
- [68] Lamphear JG, Mollick JA, Reda KB, et al. Residues near the amino and carboxyl termini of staphylococcal enterotoxin E independently mediate TCR V β -specific interactions. *J Immunol.* 1996;156(6):2178–2185. doi: [10.4049/jimmunol.156.6.2178](https://doi.org/10.4049/jimmunol.156.6.2178)
- [69] Grossman D, Van M, Mollick JA, et al. Mutation of the disulfide loop in staphylococcal enterotoxin A. Consequences for T cell recognition. *J Immunol.* 1991;147(10):3274–3281. doi: [10.4049/jimmunol.147.10.3274](https://doi.org/10.4049/jimmunol.147.10.3274)
- [70] Wang X, Xu M, Cai Y, et al. Functional analysis of the disulphide loop mutant of staphylococcal enterotoxin C2. *Appl Microbiol BioTechnol.* 2009;82(5):861–871. doi: [10.1007/s00253-008-1800-z](https://doi.org/10.1007/s00253-008-1800-z)
- [71] Creighton TE. Disulphide bonds and protein stability. *Bioessays.* 1988;8(2):57–63. doi: [10.1002/bies.950080204](https://doi.org/10.1002/bies.950080204)
- [72] Gupta A, Van Vlijmen HW, Singh J. A classification of disulfide patterns and its relationship to protein structure and function. *Protein Sci.* 2004;13(8):2045–2058. doi: [10.1110/ps.04613004](https://doi.org/10.1110/ps.04613004)
- [73] Acharya KR, Passalacqua EF, Jones EY, et al. Structural basis of superantigen action inferred from crystal structure of toxic-shock syndrome toxin-1. *Nature.* 1994;367(6458):94–97. doi: [10.1038/367094a0](https://doi.org/10.1038/367094a0)
- [74] Dinges MM, Orwin PM, Schlievert PM. Exotoxins of *Staphylococcus aureus*. *Clin Microbiol Rev.* 2000;13(1):16–34. doi: [10.1128/cmr.13.1.16](https://doi.org/10.1128/cmr.13.1.16)
- [75] Mollick JA, Chintagumpala M, Cook RG, et al. Staphylococcal exotoxin activation of T cells. Role of exotoxin-MHC class II binding affinity and class II isotype. *J Immunol.* 1991;146(2):463–468. doi: [10.4049/jimmunol.146.2.463](https://doi.org/10.4049/jimmunol.146.2.463)
- [76] Papageorgiou AC, Acharya KR, Shapiro R, et al. Crystal structure of the superantigen enterotoxin C2 from *Staphylococcus aureus* reveals a zinc-binding site. *Structure.* 1995;3(8):769–779. doi: [10.1016/s0969-2126\(01\)00212-x](https://doi.org/10.1016/s0969-2126(01)00212-x)
- [77] Schad EM, Papageorgiou AC, Svensson LA, et al. A structural and functional comparison of staphylococcal enterotoxins A and C2 reveals remarkable similarity and dissimilarity. *J Mol Biol.* 1997;269(2):270–280. doi: [10.1006/jmbi.1997.1023](https://doi.org/10.1006/jmbi.1997.1023)